Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 828 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,247 shares of the specialty pharmaceutical company’s stock after selling 828 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Jazz Pharmaceuticals were worth $672,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BB&T Securities LLC boosted its stake in shares of Jazz Pharmaceuticals by 26.7% in the 3rd quarter. BB&T Securities LLC now owns 3,906 shares of the specialty pharmaceutical company’s stock valued at $505,000 after purchasing an additional 824 shares during the last quarter. Hardman Johnston Global Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 7.1% in the 3rd quarter. Hardman Johnston Global Advisors LLC now owns 36,120 shares of the specialty pharmaceutical company’s stock valued at $4,628,000 after purchasing an additional 2,410 shares during the last quarter. Chicago Equity Partners LLC boosted its stake in shares of Jazz Pharmaceuticals by 3.1% in the 3rd quarter. Chicago Equity Partners LLC now owns 17,285 shares of the specialty pharmaceutical company’s stock valued at $2,215,000 after purchasing an additional 525 shares during the last quarter. Hancock Whitney Corp boosted its stake in shares of Jazz Pharmaceuticals by 739.1% in the 3rd quarter. Hancock Whitney Corp now owns 33,604 shares of the specialty pharmaceutical company’s stock valued at $4,306,000 after purchasing an additional 29,599 shares during the last quarter. Finally, MAI Capital Management boosted its stake in shares of Jazz Pharmaceuticals by 9.6% in the 3rd quarter. MAI Capital Management now owns 4,784 shares of the specialty pharmaceutical company’s stock valued at $613,000 after purchasing an additional 420 shares during the last quarter. 87.71% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals stock opened at $130.14 on Friday. The company’s 50 day simple moving average is $124.77 and its 200 day simple moving average is $131.70. Jazz Pharmaceuticals PLC has a fifty-two week low of $113.52 and a fifty-two week high of $154.44. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of 10.63, a PEG ratio of 1.57 and a beta of 1.09. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 28.57%. The business had revenue of $537.70 million for the quarter, compared to analyst estimates of $523.92 million. During the same quarter last year, the firm earned $3.58 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 14.6% compared to the same quarter last year. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 13.54 EPS for the current fiscal year.

Several research analysts have recently issued reports on JAZZ shares. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 target price on the stock. in a research note on Friday, September 13th. HC Wainwright reaffirmed a “hold” rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 14th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $150.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, October 14th. Finally, ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $165.71.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 4,371 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. Following the sale, the chief executive officer now owns 311,855 shares in the company, valued at $40,541,150. The disclosure for this sale can be found here. Insiders have sold a total of 5,371 shares of company stock worth $730,575 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: What is dollar cost averaging (DCA)?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.